Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Of The Fortnight Sees More Conflicting Indicators For Biotech VC

This article was originally published in The Pink Sheet Daily

Executive Summary

Quarterly trends suggest the outlook may turn sunny, plus financings updates on NuPathe, Euthymics Bioscience, Xoma and Immune Design Corp.

You may also be interested in...

As VC Investments Rebound In Q2, Skepticism Lingers

A quarterly report shows an uptick in VC disbursements, but LP commitments are still lagging.

Financings Of The Fortnight: Is Venture Capital's Glass Half-Full Or Half-Empty?

Fundraising successes by Trevena, Sunesis, Calithera and iPierian highlight the last two weeks' action.

As Some VCs Run On Empty, Others Are Topping Off The Tank

New money is increasingly hard to come by for life sciences venture capital firms. Start-Up tracks VCs to determine which firms have older vintage funds and which have plenty of fresh capital to invest.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts